CD8A and COVID-19: Recent suggestions to therapeutically administer checkpoint inhibitors, which are efficiently used for tumor immune therapy, for the treatment of COVID-19 patients (37) should be reevaluated, since we did not find functionally exhausted CD8+ T cells in our patients.